In the ToGA trial, treatment with the anti-HER2 monoclonal antibody, trastuzumab, showed improved outcomes in combination with chemotherapy versus chemotherapy alone in patients with HER2-positive GC [9]. The gene discussed is ERBB2; the disease is gastric cancer.